SEAGEN INC.
Presentation Operator MessageOperator (Operator)Good day, and welcome to Seagen's 2021 Annual ...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Seagen Inc. est spécialisé dans le développement et la commercialisation de thérapies à base d'anticorps monoclonaux destinées au traitement du cancer. Le CA par source de revenus se répartit comme suit :
- ventes de produits (87%) ;
- royalties (8,4%) ;
- revenus issus d'accords de collaboration et de licence (4,6%).
Calendar
2024-07-24
- Q2 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| +26.37% | 48.16B | |
| -1.01% | 41.73B | |
| +46.00% | 41.03B | |
| -5.31% | 28.77B | |
| +9.34% | 25.59B | |
| -21.69% | 18.96B | |
| +6.23% | 12.92B | |
| +26.99% | 12.03B | |
| -3.38% | 11.77B |
